Opinion
Video
Author(s):
Tiffany A. Traina, MD, presents a patient case involving a woman diagnosed with HR-negative, HER2 3+ invasive ductal adenocarcinoma and elaborates on the clinical management approaches employed in her treatment sequencing.
Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer
Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa
Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy
Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping Alterations
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC
Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium